Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia

The outcome of older (≥ 60 years) acute myeloid leukemia (AML) patients is poor, and novel treatments are needed. In a phase 2 trial for older AML patients, low-dose (20 mg/m(2) per day for 10 days) decitabine, a DNA hypomethylating azanucleoside, produced 47% complete response rate with an excellen...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Yan, Pearlly, Frankhouser, David, Murphy, Mark, Tam, Hok-Hei, Rodriguez, Benjamin, Curfman, John, Trimarchi, Michael, Geyer, Susan, Wu, Yue-Zhong, Whitman, Susan P., Metzeler, Klaus, Walker, Alison, Klisovic, Rebecca, Jacob, Samson, Grever, Michael R., Byrd, John C., Bloomfield, Clara D., Garzon, Ramiro, Blum, William, Caligiuri, Michael A., Bundschuh, Ralf, Marcucci, Guido
التنسيق: Artigo
اللغة:Inglês
منشور في: American Society of Hematology 2012
الموضوعات:
Myeloid Neoplasia
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC3448258/
https://ncbi.nlm.nih.gov/pubmed/22786882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-05-429175
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة